Related references
Note: Only part of the references are listed.Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort
Dany P. Perocheau et al.
HUMAN GENE THERAPY (2019)
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Benjamin J. Samelson-Jones et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates
Michela Milani et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Update on clinical gene therapy for hemophilia
George Q. Perrin et al.
BLOOD (2019)
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B
Wolfgang Miesbach et al.
BLOOD (2018)
Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy
Hildegund C. J. Ertl et al.
HUMAN GENE THERAPY (2017)
Gene Therapy for Hemophilia
Arthur W. Nienhuis et al.
MOLECULAR THERAPY (2017)
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
L. A. George et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
AAV5-Factor VIII Gene Transfer in Severe Hemophilia A
Savita Rangarajan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Advances in the treatment of bleeding disorders
F. Peyvandi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
The past and future of haemophilia: diagnosis, treatments, and its complications
Flora Peyvandi et al.
LANCET (2016)
Self-Complementary Adeno-Associated Virus Vectors Improve Transduction Efficiency of Corneal Endothelial Cells
Anja K. Gruenert et al.
PLOS ONE (2016)
Genome editing: progress and challenges for medical applications
Dana Carroll
GENOME MEDICINE (2016)
Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models
Joshua I. Siner et al.
JCI INSIGHT (2016)
Haemophilia gene therapy: Progress and challenges
Elsa Lheriteau et al.
BLOOD REVIEWS (2015)
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
A. C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype
Joshua I. Siner et al.
BLOOD (2013)
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
Jenny McIntosh et al.
BLOOD (2013)
Future of coagulation factor replacement therapy
F. Peyvandi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer
George Buchlis et al.
BLOOD (2012)
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Aravind Asokan et al.
MOLECULAR THERAPY (2012)
Codon optimization of human factor VIII cDNAs leads to high-level expression
Natalie J. Ward et al.
BLOOD (2011)
Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B
Amit C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges
Deepak Raj et al.
EXPERT REVIEW OF HEMATOLOGY (2011)
Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors
Sylvie Boutin et al.
HUMAN GENE THERAPY (2010)
Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome >= 8.2kb
Yi Lai et al.
MOLECULAR THERAPY (2010)
Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy
Gregory D. Hurlbut et al.
MOLECULAR THERAPY (2010)
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Paolo Simioni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Adeno-associated virus vector Genomes persist as episomal chromatin in primate muscle
Magalie Penaud-Budloo et al.
JOURNAL OF VIROLOGY (2008)
CD8+ T-cell responses to adeno-associated virus capsid in humans
Federico Mingozzi et al.
NATURE MEDICINE (2007)
Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates
Amit C. Nathwani et al.
BLOOD (2007)
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B
Haiyan Jiang et al.
MOLECULAR THERAPY (2006)
Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia A dogs and mice
R Sarkar et al.
HUMAN GENE THERAPY (2006)
Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver
AC Nathwani et al.
BLOOD (2006)
Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response
CS Manno et al.
NATURE MEDICINE (2006)
Bioengineering of coagulation factor VIR for improved secretion
HZ Miao et al.
BLOOD (2004)
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
CS Manno et al.
BLOOD (2003)
Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo
Z Wang et al.
GENE THERAPY (2003)
Expression of human factor VIII by splicing between dimerized AAV vectors
HJ Chao et al.
MOLECULAR THERAPY (2002)
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
JD Mount et al.
BLOOD (2002)
Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo
H Nakai et al.
JOURNAL OF VIROLOGY (2001)
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
MA Kay et al.
NATURE GENETICS (2000)
Share Paper
